- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.07. | Eli Lilly tops new biopharma ranking on launch success, development speed | ||
| 28.07. | Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options | ||
| 28.07. | Altimmune's next-gen GLP-1 curbs heavy drinking in 'unequivocal' ph. 2 alcohol use disorder win | ||
| 28.07. | GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AstraZeneca's backyard | ||
| 28.07. | Atea's hepatitis C asset matches Gilead's Epclusa in phase 3 trial | ||
| 28.07. | GSK partner Hansoh reports another phase 3 win for priority ADC | ||
| 27.07. | RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC | ||
| 27.07. | MapLight shares sink on mixed phase 2 schizophrenia readout | ||
| 27.07. | Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears | ||
| 27.07. | InnoCare's oral TYK2 inhibitor clears phase 3 psoriasis test | ||
| 27.07. | After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration | ||
| 27.07. | Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug | ||
| 27.07. | AstraZeneca execs 'very confident' in homegrown ADC pipeline despite scrapping 2 candidates | ||
| 25.07. | De-Risking a Rare Disease Launch Starts with Precision | ||
| 24.07. | Amgen sheds around 40 staffers amid continuing struggles | ||
| 24.07. | Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout | ||
| 24.07. | Scribe Therapeutics records upsized $129M IPO to bankroll lipid-lowering genetic meds | ||
| 23.07. | Scancell to go public after winning reverse merger bid for troubled Neuphoria | ||
| 23.07. | Lilly's triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear | ||
| 23.07. | Australian biopharma Clinuvel to shed up to 20% of workforce in move to US | ||
| 23.07. | Roche drops TCE for lupus, but hasn't given up on autoimmune cell therapies | ||
| 22.07. | Celldex ends skin disease program after failing phase 2 test | ||
| 22.07. | Royalty Pharma pens $425M deal for slice of sales on AstraZeneca's ATTR drug | ||
| 21.07. | Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal | ||
| 21.07. | Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.